Treatment of atrial tachyarrhythmias and preexcitation syndrome with flecainide acetate
Identifieur interne : 000808 ( Main/Corpus ); précédent : 000807; suivant : 000809Treatment of atrial tachyarrhythmias and preexcitation syndrome with flecainide acetate
Auteurs : Sung Soon Kim ; Priscilla Smith ; Rodolphe RuffySource :
- The American Journal of Cardiology [ 0002-9149 ] ; 1988.
Abstract
Sixteen consecutive patients who had ventricular preexcitation complicated by atrial fibrillation or flutter were treated with intravenous flecainide acetate after treatment with as many as 5 unsuccessful trial regimens with other drugs. In 15 patients who had atrial fibrillation, the shortest RR interval during spontaneous episodes was 210 ± 39 ms (mean ± standard deviation), and the average ventricular rate was 208 ± 37 beats/min. Intravenous flecainide prevented induction of atrial fibrillation in 4 of 9 patients and eliminated anterograde accessory pathway conduction in 9 of the 16 patients. In 5 patients whose atrial fibrillation remained inducible and who continued to have preexcitation, the shortest preexcited RR interval increased from 185 ± 29 to 281 ± 46 ms (p < 0.01).Fourteen patients who had favorable responses to intravenous flecainide were given an oral regimen of the drug. Oral treatment was discontinued early because of proarrhythmic effects in 2 patients, and after 212 months because of headaches in 1 patient. Eleven patients, 5 receiving concomitant β-blockade therapy, have continued to receive a regimen of flecainide for a mean of 21 months (range 3 to 48). Seven patients have had no clinical recurrence of arrhythmias. Recurrences in 4 patients have been rare and brief with no changes in therapy required.
Url:
DOI: 10.1016/0002-9149(88)90499-7
Links to Exploration step
ISTEX:F545EAF3C078DD4C1C20968D283E7298281D156ELe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment of atrial tachyarrhythmias and preexcitation syndrome with flecainide acetate</title><author><name sortKey="Kim, Sung Soon" sort="Kim, Sung Soon" uniqKey="Kim S" first="Sung Soon" last="Kim">Sung Soon Kim</name><affiliation><mods:affiliation>From the Cardiology Division, Jewish Hospital at Washington University Medical Center, St. Louis, Missouri, USA</mods:affiliation></affiliation></author><author><name sortKey="Smith, Priscilla" sort="Smith, Priscilla" uniqKey="Smith P" first="Priscilla" last="Smith">Priscilla Smith</name><affiliation><mods:affiliation>From the Cardiology Division, Jewish Hospital at Washington University Medical Center, St. Louis, Missouri, USA</mods:affiliation></affiliation></author><author><name sortKey="Ruffy, Rodolphe" sort="Ruffy, Rodolphe" uniqKey="Ruffy R" first="Rodolphe" last="Ruffy">Rodolphe Ruffy</name><affiliation><mods:affiliation>From the Cardiology Division, Jewish Hospital at Washington University Medical Center, St. Louis, Missouri, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F545EAF3C078DD4C1C20968D283E7298281D156E</idno><date when="1988" year="1988">1988</date><idno type="doi">10.1016/0002-9149(88)90499-7</idno><idno type="url">https://api.istex.fr/document/F545EAF3C078DD4C1C20968D283E7298281D156E/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000808</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Treatment of atrial tachyarrhythmias and preexcitation syndrome with flecainide acetate</title><author><name sortKey="Kim, Sung Soon" sort="Kim, Sung Soon" uniqKey="Kim S" first="Sung Soon" last="Kim">Sung Soon Kim</name><affiliation><mods:affiliation>From the Cardiology Division, Jewish Hospital at Washington University Medical Center, St. Louis, Missouri, USA</mods:affiliation></affiliation></author><author><name sortKey="Smith, Priscilla" sort="Smith, Priscilla" uniqKey="Smith P" first="Priscilla" last="Smith">Priscilla Smith</name><affiliation><mods:affiliation>From the Cardiology Division, Jewish Hospital at Washington University Medical Center, St. Louis, Missouri, USA</mods:affiliation></affiliation></author><author><name sortKey="Ruffy, Rodolphe" sort="Ruffy, Rodolphe" uniqKey="Ruffy R" first="Rodolphe" last="Ruffy">Rodolphe Ruffy</name><affiliation><mods:affiliation>From the Cardiology Division, Jewish Hospital at Washington University Medical Center, St. Louis, Missouri, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">The American Journal of Cardiology</title><title level="j" type="abbrev">AJC</title><idno type="ISSN">0002-9149</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1988">1988</date><biblScope unit="volume">62</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="29">29</biblScope><biblScope unit="page" to="34">34</biblScope></imprint><idno type="ISSN">0002-9149</idno></series><idno type="istex">F545EAF3C078DD4C1C20968D283E7298281D156E</idno><idno type="DOI">10.1016/0002-9149(88)90499-7</idno><idno type="PII">0002-9149(88)90499-7</idno><idno type="ArticleID">88904997</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0002-9149</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Sixteen consecutive patients who had ventricular preexcitation complicated by atrial fibrillation or flutter were treated with intravenous flecainide acetate after treatment with as many as 5 unsuccessful trial regimens with other drugs. In 15 patients who had atrial fibrillation, the shortest RR interval during spontaneous episodes was 210 ± 39 ms (mean ± standard deviation), and the average ventricular rate was 208 ± 37 beats/min. Intravenous flecainide prevented induction of atrial fibrillation in 4 of 9 patients and eliminated anterograde accessory pathway conduction in 9 of the 16 patients. In 5 patients whose atrial fibrillation remained inducible and who continued to have preexcitation, the shortest preexcited RR interval increased from 185 ± 29 to 281 ± 46 ms (p < 0.01).Fourteen patients who had favorable responses to intravenous flecainide were given an oral regimen of the drug. Oral treatment was discontinued early because of proarrhythmic effects in 2 patients, and after 212 months because of headaches in 1 patient. Eleven patients, 5 receiving concomitant β-blockade therapy, have continued to receive a regimen of flecainide for a mean of 21 months (range 3 to 48). Seven patients have had no clinical recurrence of arrhythmias. Recurrences in 4 patients have been rare and brief with no changes in therapy required.</div></front></TEI><istex><corpusName>elsevier</corpusName><author><json:item><name>Sung Soon Kim MD</name><affiliations><json:string>From the Cardiology Division, Jewish Hospital at Washington University Medical Center, St. Louis, Missouri, USA</json:string></affiliations></json:item><json:item><name>Priscilla Smith RN</name><affiliations><json:string>From the Cardiology Division, Jewish Hospital at Washington University Medical Center, St. Louis, Missouri, USA</json:string></affiliations></json:item><json:item><name>Rodolphe Ruffy MD</name><affiliations><json:string>From the Cardiology Division, Jewish Hospital at Washington University Medical Center, St. Louis, Missouri, USA</json:string></affiliations></json:item></author><articleId><json:string>88904997</json:string></articleId><language><json:string>eng</json:string></language><abstract>Sixteen consecutive patients who had ventricular preexcitation complicated by atrial fibrillation or flutter were treated with intravenous flecainide acetate after treatment with as many as 5 unsuccessful trial regimens with other drugs. In 15 patients who had atrial fibrillation, the shortest RR interval during spontaneous episodes was 210 ± 39 ms (mean ± standard deviation), and the average ventricular rate was 208 ± 37 beats/min. Intravenous flecainide prevented induction of atrial fibrillation in 4 of 9 patients and eliminated anterograde accessory pathway conduction in 9 of the 16 patients. In 5 patients whose atrial fibrillation remained inducible and who continued to have preexcitation, the shortest preexcited RR interval increased from 185 ± 29 to 281 ± 46 ms (p > 0.01).Fourteen patients who had favorable responses to intravenous flecainide were given an oral regimen of the drug. Oral treatment was discontinued early because of proarrhythmic effects in 2 patients, and after 212 months because of headaches in 1 patient. Eleven patients, 5 receiving concomitant β-blockade therapy, have continued to receive a regimen of flecainide for a mean of 21 months (range 3 to 48). Seven patients have had no clinical recurrence of arrhythmias. Recurrences in 4 patients have been rare and brief with no changes in therapy required.</abstract><qualityIndicators><score>5.463</score><pdfVersion>1.3</pdfVersion><pdfPageSize>575.84 x 792.28 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>0</keywordCount><abstractCharCount>1345</abstractCharCount><pdfWordCount>2967</pdfWordCount><pdfCharCount>23287</pdfCharCount><pdfPageCount>6</pdfPageCount><abstractWordCount>208</abstractWordCount></qualityIndicators><title>Treatment of atrial tachyarrhythmias and preexcitation syndrome with flecainide acetate</title><pii><json:string>0002-9149(88)90499-7</json:string></pii><genre><json:string>research-article</json:string></genre><host><volume>62</volume><pii><json:string>S0002-9149(00)X0820-X</json:string></pii><editor><json:item><name>Jeffrey L. Anderson</name></json:item><json:item><name>MD</name></json:item><json:item><name>Edward L. C. Pritchett</name></json:item><json:item><name>MD</name></json:item></editor><pages><last>34</last><first>29</first></pages><conference><json:item><name>International Symposium on Supraventricular Arrhythmias: Focus on Flecainide, Paradise Island, Nassau, Bahamas 19871023 19871026</name></json:item></conference><issn><json:string>0002-9149</json:string></issn><issue>6</issue><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><title>The American Journal of Cardiology</title><publicationDate>1988</publicationDate></host><publicationDate>1988</publicationDate><copyrightDate>1988</copyrightDate><doi><json:string>10.1016/0002-9149(88)90499-7</json:string></doi><id>F545EAF3C078DD4C1C20968D283E7298281D156E</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/F545EAF3C078DD4C1C20968D283E7298281D156E/fulltext/pdf</uri></json:item><json:item><original>true</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/F545EAF3C078DD4C1C20968D283E7298281D156E/fulltext/txt</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/F545EAF3C078DD4C1C20968D283E7298281D156E/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/F545EAF3C078DD4C1C20968D283E7298281D156E/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Treatment of atrial tachyarrhythmias and preexcitation syndrome with flecainide acetate</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>ELSEVIER</publisher><availability><p>ELSEVIER</p></availability><date>1988</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Treatment of atrial tachyarrhythmias and preexcitation syndrome with flecainide acetate</title><author><persName><forename type="first">Sung Soon</forename><surname>Kim</surname></persName><roleName type="degree">MD</roleName><affiliation>From the Cardiology Division, Jewish Hospital at Washington University Medical Center, St. Louis, Missouri, USA</affiliation></author><author><persName><forename type="first">Priscilla</forename><surname>Smith</surname></persName><roleName type="degree">RN</roleName><affiliation>From the Cardiology Division, Jewish Hospital at Washington University Medical Center, St. Louis, Missouri, USA</affiliation></author><author><persName><forename type="first">Rodolphe</forename><surname>Ruffy</surname></persName><roleName type="degree">MD</roleName><note type="biography">Address for reprints: Rodolphe Ruffy, MD, Cardiology Division, Jewish Hospital at Washington University Medical Center, 216 South Kingshighway, St. Louis, Missouri 63110.</note><affiliation>Address for reprints: Rodolphe Ruffy, MD, Cardiology Division, Jewish Hospital at Washington University Medical Center, 216 South Kingshighway, St. Louis, Missouri 63110.</affiliation><affiliation>From the Cardiology Division, Jewish Hospital at Washington University Medical Center, St. Louis, Missouri, USA</affiliation></author></analytic><monogr><title level="j">The American Journal of Cardiology</title><title level="j" type="abbrev">AJC</title><idno type="pISSN">0002-9149</idno><idno type="PII">S0002-9149(00)X0820-X</idno><meeting><addName>International Symposium on Supraventricular Arrhythmias: Focus on Flecainide, Paradise Island, Nassau, Bahamas</addName><date>19871023</date><date>19871026</date></meeting><editor><persName>Jeffrey L. Anderson</persName></editor><editor><persName>MD</persName></editor><editor><persName>Edward L. C. Pritchett</persName></editor><editor><persName>MD</persName></editor><imprint><publisher>ELSEVIER</publisher><date type="published" when="1988"></date><biblScope unit="volume">62</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="29">29</biblScope><biblScope unit="page" to="34">34</biblScope></imprint></monogr><idno type="istex">F545EAF3C078DD4C1C20968D283E7298281D156E</idno><idno type="DOI">10.1016/0002-9149(88)90499-7</idno><idno type="PII">0002-9149(88)90499-7</idno><idno type="ArticleID">88904997</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1988</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Sixteen consecutive patients who had ventricular preexcitation complicated by atrial fibrillation or flutter were treated with intravenous flecainide acetate after treatment with as many as 5 unsuccessful trial regimens with other drugs. In 15 patients who had atrial fibrillation, the shortest RR interval during spontaneous episodes was 210 ± 39 ms (mean ± standard deviation), and the average ventricular rate was 208 ± 37 beats/min. Intravenous flecainide prevented induction of atrial fibrillation in 4 of 9 patients and eliminated anterograde accessory pathway conduction in 9 of the 16 patients. In 5 patients whose atrial fibrillation remained inducible and who continued to have preexcitation, the shortest preexcited RR interval increased from 185 ± 29 to 281 ± 46 ms (p < 0.01).Fourteen patients who had favorable responses to intravenous flecainide were given an oral regimen of the drug. Oral treatment was discontinued early because of proarrhythmic effects in 2 patients, and after 212 months because of headaches in 1 patient. Eleven patients, 5 receiving concomitant β-blockade therapy, have continued to receive a regimen of flecainide for a mean of 21 months (range 3 to 48). Seven patients have had no clinical recurrence of arrhythmias. Recurrences in 4 patients have been rare and brief with no changes in therapy required.</p></abstract></profileDesc><revisionDesc><change when="1988">Published</change></revisionDesc></teiHeader></istex:fulltextTEI></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: tail"><istex:xmlDeclaration>version="1.0" encoding="UTF-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="fla" xml:lang="en"><item-info><jid>AJC</jid><aid>88904997</aid><ce:pii>0002-9149(88)90499-7</ce:pii><ce:doi>10.1016/0002-9149(88)90499-7</ce:doi><ce:copyright type="unknown" year="1988"></ce:copyright></item-info><head><ce:title>Treatment of atrial tachyarrhythmias and preexcitation syndrome with flecainide acetate</ce:title><ce:author-group><ce:author><ce:given-name>Sung Soon</ce:given-name><ce:surname>Kim</ce:surname><ce:degrees>MD</ce:degrees></ce:author><ce:author><ce:given-name>Priscilla</ce:given-name><ce:surname>Smith</ce:surname><ce:degrees>RN</ce:degrees></ce:author><ce:author><ce:given-name>Rodolphe</ce:given-name><ce:surname>Ruffy</ce:surname><ce:degrees>MD</ce:degrees><ce:cross-ref refid="COR1"><ce:sup loc="post">∗</ce:sup></ce:cross-ref></ce:author><ce:affiliation><ce:textfn>From the Cardiology Division, Jewish Hospital at Washington University Medical Center, St. Louis, Missouri, USA</ce:textfn></ce:affiliation><ce:correspondence id="COR1"><ce:label>∗</ce:label><ce:text>Address for reprints: Rodolphe Ruffy, MD, Cardiology Division, Jewish Hospital at Washington University Medical Center, 216 South Kingshighway, St. Louis, Missouri 63110.</ce:text></ce:correspondence></ce:author-group><ce:abstract class="author"><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para view="all" id="simple-para.0010">Sixteen consecutive patients who had ventricular preexcitation complicated by atrial fibrillation or flutter were treated with intravenous flecainide acetate after treatment with as many as 5 unsuccessful trial regimens with other drugs. In 15 patients who had atrial fibrillation, the shortest RR interval during spontaneous episodes was 210 ± 39 ms (mean ± standard deviation), and the average ventricular rate was 208 ± 37 beats/min. Intravenous flecainide prevented induction of atrial fibrillation in 4 of 9 patients and eliminated anterograde accessory pathway conduction in 9 of the 16 patients. In 5 patients whose atrial fibrillation remained inducible and who continued to have preexcitation, the shortest preexcited RR interval increased from 185 ± 29 to 281 ± 46 ms (p < 0.01).</ce:simple-para><ce:simple-para view="all" id="simple-para.0015">Fourteen patients who had favorable responses to intravenous flecainide were given an oral regimen of the drug. Oral treatment was discontinued early because of proarrhythmic effects in 2 patients, and after <math altimg="si1.gif">2<fr shape="case" align="c" style="s"><nu>1</nu><de>2</de></fr></math> months because of headaches in 1 patient. Eleven patients, 5 receiving concomitant β-blockade therapy, have continued to receive a regimen of flecainide for a mean of 21 months (range 3 to 48). Seven patients have had no clinical recurrence of arrhythmias. Recurrences in 4 patients have been rare and brief with no changes in therapy required.</ce:simple-para></ce:abstract-sec></ce:abstract></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Treatment of atrial tachyarrhythmias and preexcitation syndrome with flecainide acetate</title></titleInfo><titleInfo type="alternative" lang="en" contentType="CDATA"><title>Treatment of atrial tachyarrhythmias and preexcitation syndrome with flecainide acetate</title></titleInfo><name type="personal"><namePart type="given">Sung Soon</namePart><namePart type="family">Kim</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>From the Cardiology Division, Jewish Hospital at Washington University Medical Center, St. Louis, Missouri, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Priscilla</namePart><namePart type="family">Smith</namePart><namePart type="termsOfAddress">RN</namePart><affiliation>From the Cardiology Division, Jewish Hospital at Washington University Medical Center, St. Louis, Missouri, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Rodolphe</namePart><namePart type="family">Ruffy</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>From the Cardiology Division, Jewish Hospital at Washington University Medical Center, St. Louis, Missouri, USA</affiliation><description>Address for reprints: Rodolphe Ruffy, MD, Cardiology Division, Jewish Hospital at Washington University Medical Center, 216 South Kingshighway, St. Louis, Missouri 63110.</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article"></genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1988</dateIssued><copyrightDate encoding="w3cdtf">1988</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="en">Sixteen consecutive patients who had ventricular preexcitation complicated by atrial fibrillation or flutter were treated with intravenous flecainide acetate after treatment with as many as 5 unsuccessful trial regimens with other drugs. In 15 patients who had atrial fibrillation, the shortest RR interval during spontaneous episodes was 210 ± 39 ms (mean ± standard deviation), and the average ventricular rate was 208 ± 37 beats/min. Intravenous flecainide prevented induction of atrial fibrillation in 4 of 9 patients and eliminated anterograde accessory pathway conduction in 9 of the 16 patients. In 5 patients whose atrial fibrillation remained inducible and who continued to have preexcitation, the shortest preexcited RR interval increased from 185 ± 29 to 281 ± 46 ms (p < 0.01).Fourteen patients who had favorable responses to intravenous flecainide were given an oral regimen of the drug. Oral treatment was discontinued early because of proarrhythmic effects in 2 patients, and after 212 months because of headaches in 1 patient. Eleven patients, 5 receiving concomitant β-blockade therapy, have continued to receive a regimen of flecainide for a mean of 21 months (range 3 to 48). Seven patients have had no clinical recurrence of arrhythmias. Recurrences in 4 patients have been rare and brief with no changes in therapy required.</abstract><relatedItem type="host"><titleInfo><title>The American Journal of Cardiology</title></titleInfo><titleInfo type="abbreviated"><title>AJC</title></titleInfo><name type="conference"><namePart>International Symposium on Supraventricular Arrhythmias: Focus on Flecainide, Paradise Island, Nassau, Bahamas</namePart><namePart type="date">19871023</namePart><namePart type="date" encoding="w3cdtf">19871026</namePart></name><name type="personal"><namePart>Jeffrey L. Anderson</namePart><role><roleTerm type="text">editor</roleTerm></role></name><name type="personal"><namePart>MD</namePart><role><roleTerm type="text">editor</roleTerm></role></name><name type="personal"><namePart>Edward L. C. Pritchett</namePart><role><roleTerm type="text">editor</roleTerm></role></name><name type="personal"><namePart>MD</namePart><role><roleTerm type="text">editor</roleTerm></role></name><genre type="Journal">journal</genre><originInfo><dateIssued encoding="w3cdtf">19880825</dateIssued></originInfo><identifier type="ISSN">0002-9149</identifier><identifier type="PII">S0002-9149(00)X0820-X</identifier><part><date>19880825</date><detail type="issue"><title>International Symposium on Supraventricular Arrhythmias: Focus on Flecainide, Paradise Island, Nassau, Bahamas</title></detail><detail type="volume"><number>62</number><caption>vol.</caption></detail><detail type="issue"><number>6</number><caption>no.</caption></detail><extent unit="issue pages"><start>1</start><end>67</end></extent><extent unit="pages"><start>29</start><end>34</end></extent></part></relatedItem><identifier type="istex">F545EAF3C078DD4C1C20968D283E7298281D156E</identifier><identifier type="DOI">10.1016/0002-9149(88)90499-7</identifier><identifier type="PII">0002-9149(88)90499-7</identifier><identifier type="ArticleID">88904997</identifier><recordInfo><recordContentSource>ELSEVIER</recordContentSource></recordInfo></mods></metadata><enrichments><istex:refBibTEI uri="https://api.istex.fr/document/F545EAF3C078DD4C1C20968D283E7298281D156E/enrichments/refBib"><teiHeader></teiHeader><text><front></front><body></body><back><listBibl><biblStruct><monogr><title level="m" type="main">Techniques and Interpretations. Philadelphia: Lea & Feb-iger</title><author><persName><forename type="first">A</forename><surname>Symposium</surname></persName></author><author><persName><surname>Focus</surname></persName></author><author><persName><surname>Flecainide</surname></persName></author><author><persName><surname>Electrophysiology</surname></persName></author><imprint><date type="published" when="1979"></date><biblScope unit="page" from="147" to="90"></biblScope></imprint></monogr></biblStruct><biblStruct><monogr><title level="m" type="main">Thepreexcita-tion syndromes</title><author><persName><forename type="middle">Jj</forename><surname>Gallagher</surname></persName></author><author><persName><surname>Pritchett El</surname></persName></author><author><persName><surname>Scaly Wc</surname></persName></author><author><persName><forename type="middle">J</forename><surname>Kasell</surname></persName></author><imprint><date type="published" when="1978"></date><biblScope unit="page" from="285" to="327"></biblScope><pubPlace>Prog Cardiouasc Dis</pubPlace></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Ventricularfibrillation in the Wolff-Parkinson-White syndrome</title><author><persName><surname>Kl</surname></persName></author><author><persName><surname>Gj</surname></persName></author><author><persName><forename type="middle">Tm</forename><surname>Bashore</surname></persName></author><author><persName><forename type="middle">Td</forename><surname>Sellers</surname></persName></author><author><persName><surname>Pritchett</surname></persName></author><author><persName><surname>Elc</surname></persName></author><author><persName><forename type="middle">Wm</forename><surname>Smith</surname></persName></author><author><persName><surname>Gallagher</surname></persName></author><author><persName><surname>Jj</surname></persName></author></analytic><monogr><title level="j">N Engl J Med</title><imprint><biblScope unit="volume">301</biblScope><biblScope unit="page" from="1080" to="1085"></biblScope><date type="published" when="1979"></date></imprint></monogr></biblStruct><biblStruct><monogr><title level="m" type="main">Effect of drugs in the Wolff-Parkinson-White syndrome: importance of initial length of effective refractory period of the accessory pathway</title><author><persName><surname>Wel</surname></persName></author><author><persName><surname>Hjj</surname></persName></author><author><persName><surname>Bar Fw</surname></persName></author><author><persName><surname>Dassen Wrm</surname></persName></author><author><persName><forename type="middle">P</forename><surname>Brugada</surname></persName></author><author><persName><surname>Vanagt Ej</surname></persName></author><author><persName><surname>Farre</surname></persName></author><imprint><biblScope unit="page" from="46665" to="669"></biblScope><pubPlace>Am J Cardiol1980</pubPlace></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Experience with 118 consecutive patients undergoing operation for the Wolff-Parkinson-White syndrotvte</title><author><persName><surname>Cox</surname></persName></author><author><persName><surname>Jl</surname></persName></author><author><persName><forename type="middle">Jj</forename><surname>Gallagher</surname></persName></author><author><persName><surname>Cai</surname></persName></author><author><persName><surname>Me</surname></persName></author></analytic><monogr><title level="j">J Thorac Car-diouasc Surg</title><imprint><biblScope unit="volume">90</biblScope><biblScope unit="page" from="490" to="501"></biblScope><date type="published" when="1985"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">McLel l an DG. Surgery for Wolff-Parkinson-White syndrome: further experience with an epicardial approach</title><author><persName><surname>Gui</surname></persName></author><author><persName><surname>Gm</surname></persName></author><author><persName><surname>Ei</surname></persName></author><author><persName><surname>Gj</surname></persName></author><author><persName><forename type="middle">Ad</forename><surname>Sharma</surname></persName></author><author><persName><surname>Jones</surname></persName></author></analytic><monogr><title level="j">Circulation</title><imprint><biblScope unit="volume">74</biblScope><biblScope unit="page" from="525" to="529"></biblScope><date type="published" when="1986"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Efficacy and safety of transcatheter ablation of posteroseptal accessory pathways</title><author><persName><forename type="middle">F</forename><surname>Morady</surname></persName></author><author><persName><surname>Scheinman Mm</surname></persName></author><author><persName><surname>Wi</surname></persName></author><author><persName><forename type="first">Di</forename><surname>Sa</surname></persName></author><author><persName><surname>Carl</surname></persName></author><author><persName><forename type="first">Davis</forename><forename type="middle">Jc</forename><surname>La</surname></persName></author><author><persName><forename type="first">Griffin</forename><forename type="middle">Jc M</forename><surname>Ruder</surname></persName></author><author><persName><forename type="first">Abbott</forename><forename type="middle">Ja</forename><surname>Eldar</surname></persName></author></analytic><monogr><title level="j">Circulation</title><imprint><biblScope unit="volume">72</biblScope><biblScope unit="page" from="170" to="177"></biblScope><date type="published" when="1985"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Encainide for treatment of supraoentricular tachycardias associated with the Wolfjf-Parkinson-White syndrome</title><author><persName><surname>Markel Ml</surname></persName></author><author><persName><surname>Prystowsky En</surname></persName></author><author><persName><surname>Heger</surname></persName></author><author><persName><forename type="first">Miles</forename><forename type="middle">Wm</forename><surname>Jj</surname></persName></author><author><persName><forename type="middle">N</forename><surname>Fineberg</surname></persName></author><author><persName><surname>Dp</surname></persName></author></analytic><monogr><title level="j">Am J Cardiol</title><imprint><biblScope unit="page" from="5841" to="48"></biblScope><date type="published" when="1986"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Electrophysio-logic effects of disopyramide phosphate inpatients with Woljjf-Parkinson-White syndrome Paroxysmal atrialfibrillation in the Wolff-Parkin-son-White syndrome</title><author><persName><surname>Kerr Cr</surname></persName></author><author><persName><surname>Prystowsky</surname></persName></author><author><persName><surname>En</surname></persName></author><author><persName><forename type="middle">Wm</forename><surname>Smith</surname></persName></author><author><persName><forename type="middle">L</forename><surname>Cook</surname></persName></author><author><persName><surname>Gallagher</surname></persName></author><author><persName><forename type="first">Wyndham</forename><forename type="middle">Ra Cr</forename><surname>Bauernfeind</surname></persName></author><author><persName><surname>Swiryn</surname></persName></author><author><persName><surname>Sp</surname></persName></author><author><persName><forename type="middle">Ev</forename><surname>Pa&o</surname></persName></author><author><persName><forename type="middle">B</forename><surname>Strasberg</surname></persName></author><author><persName><forename type="first">W</forename><surname>Lam</surname></persName></author><author><persName><forename type="middle">D</forename><surname>Westveer</surname></persName></author><author><persName><surname>Rosen</surname></persName></author><author><persName><surname>Km</surname></persName></author></analytic><monogr><title level="j">Circulation Am J Cardiol</title><imprint><biblScope unit="volume">647</biblScope><biblScope unit="issue">16</biblScope><biblScope unit="page" from="869" to="878562"></biblScope><date type="published" when="1981"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Atrialfibrillation in patients with Wolff-Parkinson-White syndrome: incidence after surgical abla-tion of the accessory pathway</title><author><persName><surname>Sharma Ad</surname></persName></author><author><persName><surname>Ei</surname></persName></author><author><persName><surname>Gj</surname></persName></author><author><persName><surname>Gui</surname></persName></author><author><persName><surname>Gm</surname></persName></author><author><persName><surname>Milstein</surname></persName></author></analytic><monogr><title level="j">Circulation</title><imprint><biblScope unit="volume">72</biblScope><biblScope unit="page" from="161" to="169"></biblScope><date type="published" when="1985"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Mechanisms of spontaneous alternation between reciprocating tachycardia and atria1 jlutter-fibrillation in the Wolff-Parkinson-White syndrome</title><author><persName><forename type="first">Castellanos</forename><forename type="middle">Rj A</forename><surname>Sung</surname></persName></author><author><persName><surname>Sm</surname></persName></author><author><persName><surname>Bloom Mg</surname></persName></author><author><persName><forename type="first">H</forename><surname>Gel</surname></persName></author><author><persName><surname>Myerburg</surname></persName></author></analytic><monogr><title level="j">Circulation</title><imprint><biblScope unit="volume">56</biblScope><biblScope unit="page" from="409" to="416"></biblScope><date type="published" when="1977"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Effects of cycle length on atria1 vulnerability</title><author><persName><forename type="first">Wyndham</forename><forename type="middle">Crc</forename><surname>Amat</surname></persName></author><author><persName><forename type="first">Leon</forename><forename type="middle">F D</forename><surname>Wu</surname></persName></author><author><persName><forename type="first">Denes</forename><forename type="middle">P R</forename><surname>Dhingra</surname></persName></author><author><persName><forename type="middle">R</forename><surname>Simpson</surname></persName></author><author><persName><surname>Rosen</surname></persName></author></analytic><monogr><title level="j">Circulation</title><imprint><date type="published" when="1977"></date></imprint></monogr></biblStruct><biblStruct><monogr><imprint><biblScope unit="page" from="260" to="267"></biblScope></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Sensitiuity and specificity of inoasive and noninuasioe testing for risk of sudden death in Wolff-Parkinson-White syndrome</title><author><persName><surname>Sharma</surname></persName></author><author><persName><surname>Ad</surname></persName></author><author><persName><forename type="middle">R</forename><surname>Yee</surname></persName></author><author><persName><forename type="first">G</forename><surname>Gui</surname></persName></author></analytic><monogr><title level="j">JACC</title><imprint><biblScope unit="volume">10</biblScope><biblScope unit="page" from="373" to="381"></biblScope><date type="published" when="1987"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Electrophysiologic testing in the management ofpatients with the Wolff-Parkin-son-White syndrome and atria1 fibrillation</title><author><persName><forename type="middle">F</forename><surname>Morady</surname></persName></author><author><persName><forename type="middle">C</forename><surname>Sledge</surname></persName></author><author><persName><forename type="middle">E</forename><surname>Shen</surname></persName></author><author><persName><forename type="first">Gonzales</forename><forename type="middle">Rj R</forename><surname>Sung</surname></persName></author><author><persName><surname>Scheinman</surname></persName></author><author><persName><surname>Mm</surname></persName></author></analytic><monogr><title level="j">Am J Cardiol</title><imprint><biblScope unit="volume">51</biblScope><biblScope unit="page" from="1623" to="1628"></biblScope><date type="published" when="1983"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Classification by type of uen-triculnr arrhythmia predicts frequency of adoerse cardiac events fromflecainide Minnesota): You men-ceiving those medications? tioned that 3 of the 10 who had no recurrences were Dr. Ruffy: Some patients had recurrences early in taking a concomitant /3 blocker or calcium channel inhibi-their treatment that made them desire additional thera-tor. Were the 3 patients receiving those drugs at the time py, and we usually added a /I blocker or calcium antago-you did the initial electrophysiologic study? nist. Other patients were placed on p blockers or calcium Dr</title><author><persName><forename type="first">Anderson</forename><forename type="middle">J Jl</forename><surname>Morganroth</surname></persName></author><author><persName><surname>Gentzkow</surname></persName></author><author><persName><surname>Gd</surname></persName></author></analytic><monogr><title level="j">JACC Rodolphe Ruffy 34D THE AMERICAN JOURNAL OF CARDIOLOGY</title><editor>Discussion Dr. Richard Wilson (St. Paul</editor><imprint><biblScope unit="volume">8</biblScope><biblScope unit="issue">62</biblScope><biblScope unit="page" from="607" to="615"></biblScope><date type="published" when="1986"></date></imprint></monogr><note>antagonists. for diseases such as angina pectoris or hyper-Dr. Wilson: At what point did the patients begin re-tension</note></biblStruct></listBibl></back></text></istex:refBibTEI></enrichments><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000808 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000808 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:F545EAF3C078DD4C1C20968D283E7298281D156E
|texte= Treatment of atrial tachyarrhythmias and preexcitation syndrome with flecainide acetate
}}
| This area was generated with Dilib version V0.6.23. |  |